After completing his studies in human medicine at the Ludwig-Maximilians University of Munich, Martin Eichhorn completed a 2-year postdoctoral research fellowship at the Institute for Surgical Research at the University of Munich. The main focus of his scientific work was the preclinical development of antiangiogenic and antivascular tumor therapy strategies and their translation into clinical application. After completing general surgery and thoracic surgery specialist training at Munich University Hospital, he joined the Thoraxklinik Heidelberg in 2013. He currently has the position of a senior surgeon and deputy chief physician of the surgical department at Thoraxklinik Heidelberg.
Expertise
The group is focusing on the development and optimization of new multimodal treatment strategies for thoracic malignancies. In lung cancer, the focus is currently on neoadjuvant immunotherapy. Efficacy, safety, mode of action and novel biomarker are being investigated in clinical phase I/II studies. In addition to lung cancer, multimodal therapy of pleural mesothelioma including hyperthermic chemoperfusion is in the scope of the research group.
Furthermore, the development of new robotic minimal-invasive surgical techniques as well as the analysis of existing techniques is conducted under medical and economic aspects.
- Multimodal therapy of lung cancer
- Multimodal therapy of pleural mesothelioma
- Minimal-invasive robotic thoracic surgery
Lung cancer
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial. Eichhorn ME, Niedermaier B, Charoentong P, Klotz LV, Baum P, Griffo R, Allgäuer M, Stenzinger A, Bischoff H, Schneider MA, Christopoulos P, Haberkorn U, Heußel CP, Savai R, Roberti MP, Zoernig I, Jäger D, Herth F, Thomas M, Winter H, Eichhorn F. J Immunother Cancer. 2025 Aug 4;13(8):e011874. doi: 10.1136/jitc-2025-011874.
Impact of the number of involved lymph node zones on survival in stage IIIA-N2 lung adeno and squamous cell carcinoma. Griffo R, Hoffmann H, Safi S, Eichhorn F, Klotz LV, Muley T, Baum P, Kriegsmann M, Bischoff H, Winter H, Eichhorn ME. Interdiscip Cardiovasc Thorac Surg. 2025 Jun 4;40(6):ivaf121. doi: 10.1093/icvts/ivaf121.
Robot-Assisted Versus Open Surgery for the Resection of Large Thymomas: A Retrospective Cohort Study. Niedermaier B, Griffo R, Eichhorn F, Klotz LV, Grosch H, Muley T, Winter H, Eichhorn ME.J Surg Oncol. 2025 Jun;131(8):1543-1550. doi: 10.1002/jso.28113.
Dr. Alessio Campisi | Thoracic Surgeon, Research Fellow | ||
Dr. med. B. Niedermaier | Assistenzarzt, klinischer Wissenschaftler | ||
Dr. med. R. Griffo | Fachärztin für Thoraxchirurgie, klinische Wissenschaftlerin | ||
S. Lo Giudice | Study Nurse | ||
P. Schmierer | Assistenzarzt, Doktorand |
Lung Research - Projects
- Neoadjuvant immunotherapy for operable lung cancer:
safety and efficacy are investigated in a phase II IIT-trial (NEOMUN). The translational research project focuses on the mode of action and identification of predictive biomarker for clinical response. - Multimodal therapy for pleural mesothelioma:
Analysis of perioperative pathophysiology in the context of pleurectomy/decortication and hyperthermic chemoperfusion. Analysis of long-term survival and identification of predictive biomarkers. The effectiveness of the integration of immunotherapy in the multimodal therapy concept is investigated in a phase II trial (NICITA) - Robotic thoracic surgery (RATS):
New minimally invasive robotic surgical techniques for thoracic malignancies are developed and the long-term results of established robotic surgical procedures are analyzed. In addition to medical aspects, economic effects are analyzed.
